Eli Lilly and Company (LLY)

NASDAQ

$1062.71

+$35.20 (3.43%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$1032.55$1065.00

Open $1032.55

52 Week Range

$623.78$1111.99

Previous Close $1027.51

Market Cap953.57B

Volume3.70M

Avg Volume3.84M

P/E (TTM)51.77

EPS (TTM)$20.53

Dividend / Yield$6.23 (0.59%)

Dividend Streak12 years

Latest Press Releases for Eli Lilly and Company

DEC122025

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

Source: PRNewsWire•3 days ago

As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated disease In all patients, the imlunestrant plus abemaciclib combination achieved a median PFS of 10.9 month...

DEC112025

Prison Fellowship Awarded $5 Million Grant From Lilly Endowment Inc. To Broaden Its Reach in Sharing Stories of Radical Restoration

Source: GlobeNewsWire•4 days ago

WASHINGTON, D.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Prison Fellowship, the nation's largest Christian nonprofit serving currently and formerly incarcerated people and their families and a leading advocate for criminal justice reform, today announced ...

DEC112025

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Source: PRNewsWire•4 days ago

In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly impro...

DEC92025

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

Source: PRNewsWire•6 days ago

Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site...

DEC92025

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

Source: PRNewsWire•6 days ago

INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholl...

DEC92025

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL

Source: PRNewsWire•6 days ago

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal of Clinical Oncology and highlighted in a late-br...

DEC82025

Lilly declares first-quarter 2026 dividend

Source: PRNewsWire•7 days ago

INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, t...

DEC82025

Carolyn Bertozzi returns to Lilly board of directors

Source: PRNewsWire•7 days ago

INDIANAPOLIS , Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D....

DEC72025

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Source: PRNewsWire•8 days ago

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) populat...

DEC32025

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor

Source: PRNewsWire•12 days ago

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indication represents a substantial increase in the numb...